Drug Research
PharmAbcine signs a CMO contract with Binex so Binex can produce olinvacimab at its new 5,000L production line
PharmAbcine, a biotech company focusing on the development of antibody therapeutics, announced on August 31 that it had signed a contract manufacturing organization(CMO) agreement with Binex, a leading biologics CDMO(Contract Development and Manufacturing Organization) company in Korea.
With the new...
Drug Research
Catalent and Exelixis Enter into Collaboration, License, and Exclusive Option Agreement to Develop ADC Leveraging SMARTag Bioconjugation Technology
Exelixis, Inc. and Catalent announced a partnership under which Catalent’s Redwood Bioscience subsidiary will develop multiple antibody-drug conjugates (ADCs) for Exelixis using Catalent’s proprietary SMARTag® site-specific bioconjugation technology.
Under the terms of the agreement, Catalent will use its SMARTag® bioconjugation...
Drug Research
Enesi Pharma partners with Adelaide University for Zika vaccine
Enesi Pharma, an innovative biotechnology company developing next-generation vaccination products targeting serious diseases, is delighted to announce its partnership with the University of Adelaide to develop a new thermostable, solid dose DNA vaccine for Zika virus to prevent infection...
Drug Research
Ohio State University researchers working on promising COVID-19 vaccine
An experimental vaccine under research at The Ohio State University has shown the potential to be an option moving forward in the quest to stamp out COVID-19.
Researchers have used an engineering technique that allows for manipulation of the messenger...
Drug Research
Piramal Pharma to Collaboratewith Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs
Piramal Pharma Solutions, a leading contract development and manufacturing organization (CDMO), today announced that the company will be partnering with Epirum Bio on an exclusivemanufacturing relationship fornew orphan drugs targeting rare diseases with high unmetneeds.
The Piramal Pharma Solutions (PPS)...
Drug Research
AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases
AbbVie and Harvard University announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS) to study and develop novel therapies against emergent viral infections, with a focus on those caused by coronaviruses and...
Drug Research
Quanticate Announces new Partnership with Antev Ltd
Quanticate is pleased to partner with Antev Limited on a Phase II, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a GnRH antagonist, in Participants with Advanced Prostate Cancer.
Prostate cancer is one of the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read